ARCHIVES

Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds

This article is from The Cancer Letter archive.

Vol. 28 No. 8 | August 26, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: DeVita, Seffrin Head Committee advising Feinstein On National Cancer Revision

November 5, 1999

Protocols Approved By NCI During January 2004

February 27, 2004

Natcher Subcommittee Kills Recision, Save NCI $17 Million

May 2, 1980

In Brief: Painter Is AMA President-Elect; FDA Approves Taxol; Protocol Enrolls 150-200 A Month

August 14, 1992

Tumor Classification, Monoclonal Antibody Announcements Made

January 7, 1983

In Brief: Training Act Requires 75% Fr Institutional Grants, Rest For Individuals Fellowships

September 27, 1974